BioRestorative Therapies Gains Patent for Innovative Therapy
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”), a forward-thinking clinical stage regenerative medicine company focusing on stem cell-based therapies, proudly announces the favorable issuance of a Notice of Allowance from the European Patent Office. This approval pertains to a novel patent application for their groundbreaking ThermoStem® metabolic disease program.
Patented Manufacturing Process
The newly granted patent covers vital cGMP manufacturing processes essential for creating advanced therapeutic products. Specifically, it addresses a method of producing non-naturally occurring three-dimensional stem cell aggregates derived from brown adipose tissue. This unique innovation could significantly enhance treatment efficacy in metabolic disorders.
Acknowledging Innovation
“This patent allowance serves as strong validation for the innovative strides we are making in our metabolic disease program,” commented Lance Alstodt, the Chief Executive Officer of BioRestorative. “The potential market opportunity for ThermoStem®-infused brown adipose derived stem cells (BADSCs) is immense, especially in transforming the current treatment landscape dominated by GLP-1 therapies for obesity and related metabolic conditions.”
Future Developments on the Horizon
Earlier this year, BioRestorative disclosed their plans to develop an exosome-based biologic program aimed at combating obesity. The Company is preparing to enter the formal regulatory process with the U.S. Food and Drug Administration (FDA) by submitting a Drug Master File (DMF) for this promising candidate. Following this advancement, BioRestorative is also engaged in ongoing discussions with a commercial stage regenerative medicine entity regarding licensing agreements related to its proprietary ThermoStem® intellectual property.
About BioRestorative Therapies
For those unfamiliar, BioRestorative is committed to creating and advancing therapeutic products that leverage cell and tissue protocols, focusing heavily on adult stem cells. The Company has two core clinical development programs targeting disc/spine diseases and metabolic disorders, supplemented by a budding BioCosmeceutical product line.
Disc/Spine Therapeutics
The lead candidate under BioRestorative's Disc/Spine program is BRTX-100. This innovative therapy is derived from patients' own mesenchymal stem cells harvested from their bone marrow. This process aims to medically address painful lumbosacral disc disorders. Currently, a Phase 2 clinical trial is actively evaluating its effectiveness in alleviating chronic lower back pain due to degenerative disc disease.
Focus on Metabolic Health
As part of their Metabolic Program, the Company is pioneering cell-based therapy candidates that utilize BADSC to both mimic and enhance the body's naturally occurring brown adipose tissue (BAT). Preliminary research suggests that elevating brown fat levels in the body could lead to increased calorie burning and improved metabolic health. Furthermore, the exosomes released by these BADSC may also play a role in moderating weight loss.
Exploring BioCosmeceuticals
BioRestorative has begun offering a range of BioCosmeceutical products, featuring a proprietary cell-based secretome. This serum, developed in compliance with cGMP protocols, is specifically designed to reduce signs of aging such as fine lines and wrinkles. The firm plans to expand this product line further to include a comprehensive array of aesthetic treatments that seek FDA approvals in the fast-evolving BioCosmeceuticals market.
Frequently Asked Questions
What is BioRestorative Therapies known for?
BioRestorative Therapies is focused on developing regenerative medicine treatments based on stem cell technology, targeting conditions like metabolic diseases and spine disorders.
What recent patent did BioRestorative Therapies receive?
The Company received a Notice of Allowance for a patent related to its ThermoStem® metabolic disease program, showcasing innovative processes in stem cell production.
What is ThermoStem®?
ThermoStem® is a platform developed by BioRestorative that utilizes stem cells derived from brown adipose tissue to potentially treat obesity and metabolic disorders.
What are BioRestorative’s clinical initiatives?
The Company has ongoing clinical programs focused on treating disc-related issues with BRTX-100 and metabolic disorders through its ThermoStem® program.
How does BioRestorative plan to expand its product offerings?
BioRestorative intends to broaden its BioCosmeceutical product range and seek FDA approval to facilitate the introduction of new aesthetic treatments.
